PSMA5 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL605949	0.54	15/20
SCHEMBL607010	0.56	12/20
SCHEMBL609327	0.55	12/20
SCHEMBL607553	0.54	12/20
SCHEMBL606932	0.53	12/20
SCHEMBL608381	0.53	12/20
SCHEMBL609081	0.52	12/20
SCHEMBL606926	0.52	12/20
SCHEMBL606344	0.51	12/20
SCHEMBL606616	0.51	12/20
SCHEMBL1327404	0.50	12/20
SCHEMBL607035	0.61	11/20
SCHEMBL609733	0.60	11/20
SCHEMBL609324	0.60	11/20
SCHEMBL605158	0.59	11/20
SCHEMBL606315	0.59	11/20
SCHEMBL1477637	0.57	11/20
SCHEMBL609290	0.57	11/20
SCHEMBL607972	0.55	11/20
SCHEMBL608782	0.54	11/20

Clinical trials — most relevant to PSMA5 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease	PHASE4	UNKNOWN
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients	PHASE4	NOT_YET_RECRUITING
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes	PHASE2	UNKNOWN
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers	PHASE2	NOT_YET_RECRUITING
PS-341 Followed by Removal of Prostate for Those With Prostate Cancer	PHASE2	COMPLETED
Phase II Study of Vandetanib in Individuals With Kidney Cancer	PHASE2	COMPLETED
A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma	PHASE2	COMPLETED
The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy	PHASE2	NOT_YET_RECRUITING
A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer	PHASE2	COMPLETED
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study	PHASE2	WITHDRAWN
A Prevention Trial in Subjects at High Risk for Breast Cancer	PHASE2	COMPLETED
Biologic Correlative Taxotere/AC	PHASE2	COMPLETED
Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer	PHASE2	ACTIVE_NOT_RECRUITING
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer	PHASE1	COMPLETED
Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
GO-203-2C + Bortezomib For Relapsed Or Refractory MM	PHASE1	WITHDRAWN
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma	PHASE1	COMPLETED
A Phase I Study of Pyrimethamine in Patients With GM2 Gangliosidosis	PHASE1	WITHDRAWN
Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment	nan	UNKNOWN
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS	nan	COMPLETED
Mitochondrial Activity and Myosteatosis in the Cachexia of Cancers of the Upper Aerodigestive Tract	nan	UNKNOWN
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors	nan	NOT_YET_RECRUITING
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis	nan	UNKNOWN
Cardiovascular Complications of Carfilzomib Treatment	nan	UNKNOWN
Establishment of Human Cellular Disease Models for Wilson Disease	nan	COMPLETED
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men	nan	RECRUITING
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
The PREServation of MUScle Function in Critically Ill Patients (PRESMUS)	nan	UNKNOWN
Genetic Analysis of Gray Platelet Syndrome	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PSMA5 binder may also engage these)

Protein	Name	Similarity
P34064	—	1.000	P34064 →
Q9Z2U1	—	1.000	Q9Z2U1 →
Q5E987	—	1.000	Q5E987 →
Q9M4T8	—	1.000	Q9M4T8 →
Q95083	—	1.000	Q95083 →
O73672	—	1.000	O73672 →
Q42134	—	1.000	Q42134 →
Q10KF0	—	1.000	Q10KF0 →
Q95008	—	1.000	Q95008 →
Q8PTU1	—	1.000	Q8PTU1 →
Q8TPX5	—	0.999	Q8TPX5 →
O81149	—	0.999	O81149 →
Q8L4A7	—	0.999	Q8L4A7 →
Q9XZG5	—	0.998	Q9XZG5 →
Q94561	—	0.998	Q94561 →
B8GEZ3	—	0.998	B8GEZ3 →
A7I9C7	—	0.998	A7I9C7 →
P40301	—	0.997	P40301 →
PSMA2	Proteasome subunit alpha type-2	0.997	landscape →
A5UJS2	—	0.997	A5UJS2 →
Q59565	—	0.996	Q59565 →
Q54DM7	—	0.996	Q54DM7 →
A3CW55	—	0.996	A3CW55 →
C4KHD9	—	0.996	C4KHD9 →
C3NHC6	—	0.996	C3NHC6 →
Q55G04	—	0.995	Q55G04 →
Q27488	—	0.995	Q27488 →
C3N5R0	—	0.995	C3N5R0 →
P49722	—	0.995	P49722 →
P17220	—	0.995	P17220 →